Translational Psychiatry
March 21, 2021
Jennifer L. Kruse, Megha M Vasavada, Richard Olmstead et al.
47 citations
Abstract Inflammation plays a role in depression pathophysiology and treatment response, with effects varying by sex and therapeutic modality. Lower levels of interleukin(IL)-8 predict depression response to antidepressant medication and to electroconvulsive therapy (ECT), although ECT effects are specific to females. Whether IL-8 predicts depression response to ketamine and in a sex-specific...
American Journal of Psychiatry
March 17, 2021
Roger S McIntyre, Joshua D. Rosenblat, Charles B. Nemeroff et al.
694 citations
Replicated international studies have underscored the human and societal costs associated with major depressive disorder. Despite the proven efficacy of monoamine-based antidepressants in major depression, the majority of treated individuals fail to achieve full syndromal and functional recovery with the index and subsequent pharmacological treatments. Ketamine and esketamine represent...
Medicina
March 16, 2021
Joanna Szarmach, Wiesław Jerzy Cubała, Adam Włodarczyk et al.
14 citations
Background and Objectives: There is evidence for ketamine efficacy in treatment-resistant depression (TRD). Several safety and tolerability concerns arise that some psychotropic agents may provide blood pressure or/and heart rate alterations. The aim of this study is to review blood pressure measurements in course of the treatment with ketamine on treatment refractory inpatients with somatic...
Clinical Neurophysiology
March 14, 2021
Torsten M. Meyer, Martin Brunovský, Jiřı́ Horáček et al.
25 citations
OBJECTIVE: Ketamine has been shown to be effective in treatment of episodes of major depressive disorder (MDD). This controlled study aimed to analyse the predictive and discriminative power of heart rate (HR) and heart rate variability (HRV) for ketamine treatment in MDD. METHODS: In 51 patients, HR and HRV were assessed at baseline before and during ketamine infusion and 24 hours post...
International Journal of Clinical and Health Psychology
March 11, 2021
Adrián Pérez-aranda, Javier García-campayo, F. Gudé et al.
Background/Objective ‘Third-wave’ psychotherapies have shown effectiveness for treating psychopathological symptoms such as anxiety and depression. There is burgeoning interest in examining how these therapies’ core constructs produce their therapeutic benefits. This study explores the hypothetical mediating effect of resilience in the impact of mindfulness and self-compassion on anxiety and...
Revista Portuguesa de Psiquiatria e Saúde Mental
March 5, 2021
João Facucho-Oliveira, Daniel Esteves-Sousa, Bruno Prates et al.
Major depressive disorder affects an estimate of 5% of the population with nearly 1‑third of patients failing to achieve remission with conventional pharmacological treatment. Esketamine, a novel rapid‑acting antidepressant, with a noncompetitive antagonism on N‑methyl‑D‑Aspartate receptor, have been recently approved by Food and Drug Administration (FDA) and European Medicines Agency (EMA) for...
American Journal of Psychiatry
March 3, 2021
J. Dwyer, Angeli Landeros‐Weisenberger, Jessica A. Johnson et al.
163 citations
OBJECTIVE Adolescent depression is prevalent and is associated with significant morbidity and mortality. Although intravenous ketamine has shown efficacy in adult treatment-resistant depression, its efficacy in pediatric populations is unknown. The authors conducted an active-placebo-controlled study of ketamine's safety and efficacy in adolescents. METHODS In this proof-of-concept randomized,...
Journal of Clinical & Experimental Immunology
March 3, 2021
1 citation
Depression and post-traumatic stress disorder (PTSD), in the past two decades, has been a growing problem among adults and our youth. For hundreds, if not thousands of years, plant-based psychedelic drugs, such as psilocybin and peyote, have been utilized for medical purposes by numerous native tribal people As early as 1950, lysergic acid diethylamide (LSD), a synthetic mood-altering drug, a...
Journal of Medical Internet Research
March 2, 2021
Amy-Lee Sesel, Louise Sharpe, Heidi N Beadnall et al.
Background: Mindfulness-based stress reduction is an efficacious treatment for people with chronic health problems; however, it is highly intensive and time-consuming, which is a barrier for service provision. Objective: This study aims to develop an internet-delivered adapted version of mindfulness-based stress reduction for people with multiple sclerosis to make the intervention more...
Journal of preventive medicine and hygiene
March 1, 2021
Fateme Khajoei Nejad, Katayoun Alidousti Shahraki, Parvin Salehi Nejad et al.
Summary Background Individuals with unwanted pregnancies often experience high levels of anxiety, stress and depression that associated with maternal-neonatal outcomes. Mindfulness training is a safe and acceptable strategy to support mental health before parturition. Purpose The main objective of present study was to evaluate the influence of eight-week application of mindfulness-based stress...
Internet Interventions
March 2021
Eva Rames Nissen, Robert Zachariae, Maja O'Connor et al.
The present study investigates possible predictors of treatment response in an Internet-delivered Mindfulness-Based Cognitive Therapy (iMBCT) intervention with therapist support. This iMBCT program, a fully online delivered intervention with asynchronous therapist support, has previously been shown to be efficacious in reducing symptoms of anxiety and depression in women treated for breast...
Journal of Affective Disorders
March 1, 2021
Roger S McIntyre, Nelson B Rodrigues, Orly Lipsitz et al.
10 citations
BACKGROUND Depression severity and efficacy measurement scales employed for rapid-acting treatments (e.g., ketamine) were initially validated in adults receiving conventional monoamine-based antidepressants. The emergence of rapid-acting antidepressants in psychiatry provides the impetus for outcome measures that have been validated as sensitive to change with rapid-acting treatments. Herein,...
Journal of Psychiatric Research
March 1, 2021
Joshua D. Di Vincenzo, Ashley N. Siegel, Orly Lipsitz et al.
59 citations
The majority of antidepressant medication trials have focused on adult populations (ages 18-65), with much less research in older and younger populations. Moreover, key differences in the efficacy and safety of antidepressants have been identified between these age groups. Ketamine has emerged as a promising new treatment for treatment resistant depression (TRD). The objective of this review is...
Chonnam Research Institute of Nursing Science
February 28, 2021
Purpose: This study aimed to evaluate the effects of walking meditation on cancer patients suffering from depression and their quality of life (QoL) in a long-term care hospital. Methods: This was a quasi-experimental study with a non-equivalent control group and a pretest-posttest design. Forty-nine cancer patients living in a long-term care hospital participated in the study. The experimental...
Frontiers in Psychiatry
February 26, 2021
Marcelo Trombka, Marcelo Demarzo, Daniel Fernando Campos et al.
Background: Police officers' high-stress levels and its deleterious consequences are raising awareness to an epidemic of mental health problems and quality of life (QoL) impairment. There is a growing evidence that mindfulness-based interventions are efficacious to promote mental health and well-being among high-stress occupations. Methods: The POLICE study is a multicenter randomized...
The Journal of Clinical Psychiatry
February 23, 2021
Avinash Hosanagar, Joseph Cusimano, Rajiv Radhakrishnan
1 citation
P sychedelics have recently gained attention as compounds with therapeutic potential in the treatment of psychiatric disorders.The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designations for (±)-3,4-methylenedioxymethamphetamine (MDMA) as an adjunct to psychotherapy in severe posttraumatic stress disorder (PTSD) (in 2017) and for the adjunctive use of psilocybin with...
JMIR Research Protocols
February 22, 2021
Claudia Daudén Roquet, Corina Sas
BackgroundThe regular practice of mindfulness has been shown to provide benefits for mental well-being and prevent depression relapse. Technology-mediated interventions can facilitate the uptake and sustained practice of mindfulness, yet the evaluation of interactive systems, such as brain-computer interfaces, has been little explored. ObjectiveThe objective of this paper is to present an...
medRxiv Preprint Server
February 22, 2021
Jessica R. Gilbert, Christina S. Galiano, Allison C. Nugent et al.
preprint
The glutamatergic modulator ketamine rapidly reduces depressive symptoms in individuals with treatment-resistant major depressive disorder (MDD) and bipolar disorder. While its underlying mechanism of antidepressant action is not fully understood, modulating glutamatergically-mediated connectivity appears to be a critical component moderating antidepressant response. This double-blind,...
Neuropsychopharmacology Reports
February 21, 2021
Tomoyuki Nakamura, Masaru Tomita, N. Horikawa et al.
29 citations
Approximately one‐third of patients with major depressive disorder develop treatment‐resistant depression. One‐third of patients with treatment‐resistant depression demonstrate resistance to ketamine, which is a novel antidepressant effective for this disorder. The objective of this study was to examine the utility of resting‐state functional magnetic resonance imaging for the prediction of...
Brazilian Journal of Psychiatry
February 18, 2021
Mara C. Guimarães, Tiago M. Guimarães, Jaime E. C. Hallak et al.
41 citations
OBJECTIVE: Major depressive disorder (MDD) is related to glutamatergic dysfunction. Antagonists of glutamatergic N-methyl-D-aspartate receptor (NMDAR), such as ketamine, have antidepressant properties. Nitrous oxide (N2O) is also a NMDAR antagonist. Thus, this study aimed to evaluate the effects of augmenting antidepressant treatment with N2O. METHODS: This double blind, placebo-controlled...